Kyouichi KAIRA - My portal

Profile Information

Affiliation: Professor, Faculty of Medicine, Saitama Medical University

Researcher number: 40400783
J-GLOBAL ID: 201801013960466180
researchmap Member ID: 7000026759

Awards

Papers

Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study.

Imai H, Kaira K, Masubuchi K, Minato K

Curr Oncol, 29(1) 163-172, Dec 30, 2022 Peer-reviewed
A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab

Kuba K, Inoue H, Matsumura S, Enoki Y, Kogashiwa Y, Ebihara Y, Nakahira M, Yamazaki T, Yasuda M, Kaira K …

Sci Rep, 12(1) 22557, Dec 29, 2022 Peer-reviewed
Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1.

Yamaguchi O, Atarashi K, Yoshimura K, Shiono A, Mouri A, Nishihara F, Miura Y, Hashimoto K, Miyamoto Y, Uga H …

BMC Cancer, 22(1) 1325, Dec 17, 2022 Peer-reviewed
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy.

Kagamu H, Yamasaki S, Kitano S, Yamaguchi O, Mouri A, Shiono A, Nishihara F, Miura Y, Hashimoto K, Imai H …

Cancer Res, 82(24), Dec 16, 2022 Peer-reviewed
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.

Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A …

Thorac Cancer, 13(19) 2776-2785, Dec 1, 2022 Peer-reviewed
Potential of VEGFR2 expression as a predictive marker of PD‑1 blockade in patients with advanced NSCLC.

Kaira K, Imai H, Kawasaki T, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, Mouri A, Kobayashi K, Yasuda M …

Oncol Rep, 48(6) 214, Dec 1, 2022 Peer-reviewedLead authorCorresponding author
Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non-small cell lung cancer treated with intensity modulated radiotherapy.

Abe T, Iino M, Saito S, Aoshika T, Ryuno Y, Ohta T, Igari M, Hirai R, Kumazaki Y, Miura Y …

Thorac Cancer, 13(20) 2890-2896, Oct 1, 2022 Peer-reviewed
Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade.

Hashimoto K, Kaira K, Imai H, Mouri A, Shiono A, Miura Y, Yamaguchi O, Kobayashi K, Kagamu H, Kuji I

J Immunother, 45(8) 349-357, Oct 1, 2022 Peer-reviewedCorresponding author
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.

Imai H, Nagai Y, Minemura H, Tsuda T, Yamada Y, Wasamoto S, Kishikawa T, Shiono A, Shiihara J, Yamaguchi O …

Invest New Drugs, 40(5) 1066-1079, Oct 1, 2022 Peer-reviewed
Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa-associated lymphoid tissue lymphoma: A case report.

Shiono A, Imai H, Satou T, Taguchi R, Takahashi N, Azuma R, Yamaguchi O, Hashimoto K, Naito E, Iemura H …

Cancer Rep (Hoboken), 5(10) 1689, Oct 1, 2022 Peer-reviewed
Identification and molecular analysis of RNF31 Q622H germline polymorphism.

Nakazawa S, Mamiya R, Kawabata-Iwakawa R, Oikawa D, Kaira K, Tokunaga F, Nobusawa S, Sato Y, Sasaki A, Yajima T …

Oncol Lett, 24(5) 394, Sep 21, 2022 Peer-reviewed
Advanced Research on Immune Checkpoint Inhibitor Therapy.

Imai H, Kaira K, Kagamu H

J Clin Med, 11(18) 5392, Sep 14, 2022 Peer-reviewed
Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.

Oriuchi N, Endoh H, Kaira K

Int J Mol Sci., 23(16) 9394, Aug 20, 2022 Peer-reviewedLast author
A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.

Imai H, Fujita Y, Hiruta E, Masuno T, Yamazaki S, Tanaka H, Kamiya T, Sandoh M, Takei S, Arai K …

Thorac Cancer, 13(16) 2301-2308, Aug 1, 2022 Peer-reviewed
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).

Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K …

Ther Adv Med Oncol, 14 7588359221116603, Jul 29, 2022 Peer-reviewed
Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer.

Yamaguchi O, Kaira K, Naruse I, Umeda Y, Honda T, Watanabe S, Ichikawa K, Tateishi K, Kasahara N, Higuchi T …

Scientific Reports, 12(1) 11832, Jul 14, 2022 Peer-reviewedCorresponding author
Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer.

Kaira K

Intern Med, 62(12) 1705-1706, Jun 15, 2022 Peer-reviewedInvitedLead authorCorresponding author
The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis.

Hachisu Y, Koga Y, Kasama S, Kaira K, Uno S, Yatomi M, Aoki-Saito H, Tsurumaki H, Jingu A, Sunaga N …

Medicina (Kaunas)., 58(6) 768, Jun 6, 2022 Peer-reviewed
Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T …

Chemotherapy, 67(3) 142-150, May 5, 2022 Peer-reviewed
Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer.

Imai H, Onozato R, Kaira K, Kawashima S, Masubuchi K, Tajima K, Minato K

ncology, 100(2) 89-100, May 1, 2022 Peer-reviewed

Presentations

Management and problem of oncologic emergency in advanced lung cancer

なし

第25回アジア太平洋呼吸器学会, Nov 21, 2021
EGFR遺伝子変異陽性肺がんの EGFR-TKI治療における腫瘍内AXL発現の意義

山田忠明, 吉村彰紘, 安宅信二, 谷口寛和, 渡部聡, 三浦理, 山口博之, 内野順治, 髙山浩一, 矢野聖二

第61回日本呼吸器学会, Apr 25, 2021
EGFR遺伝子変異陽性肺がんのEGFR-TKI治療における腫瘍内AXL発現の意義

山田忠明, 吉村彰紘, 安宅信二, 谷口寛和, 渡部聡, 三浦理, 山口博之, 内野順治, 髙山浩一, 矢野聖二

第61回日本呼吸器学会, Apr 25, 2021
EGFR-TKI耐性肺癌におけるPD-1阻害剤投与後のEGFR-TKI再投与の効果

EGFR-TKI耐性肺癌におけるPD-1阻害剤投与後のEGFR-TKI再投与の効果

第61回日本呼吸器学会, Apr 25, 2021
Neuroendocrine tumor of the breast with pulmonary metastasis 30 years after mastectomy

◎Tomonori Kawasaki, Ryo Taguchi, Yuki Ichinose, Asami Nukui, Kazuo Matsuura, Takahiro Hasebe, Takashi Hojo, Akihiko Osaki, Yasuhiro Nakamura, Tetsuo Kondo, Kousuke Hashimoto, Ou Yamaguchi, Kyoichi Kaira, Hiroshi Kagamu and Toshiaki Saeki

32nd Congress of the European Society of Pathology and XXXIII International Congress of the International Academy of Pathology (Virchows Archiv), Dec 7, 2020
Neuroendocrine neoplasms of the breast showing peculiar forms of recurrence and/or metastasis

◎Tomonori Kawasaki, Anna Sapino, Motoo Ishida, Takashi Tada, Hideki Matsuya, Hiroshi Nakagomi, Toshio Oyama, Chisako Muramatsu, Jiro Ichikawa, Masao Saitoh, Tetsuo Kondo, Ryohei Katoh, Tamotsu Sugai, Yasuhiro Nakamura and Kyoichi Kaira

32nd Congress of the European Society of Pathology and XXXIII International Congress of the International Academy of Pathology (Virchows Archiv), Dec 6, 2020
Large cell neuroendocrine carcinoma of the breast showing triple negative, basal-like subtype

Sep, 2020

Research Projects

Multicenter Retrospective Study to Evaluate Docetaxel plus Ramucirumab after Combination Therapy with PD-1 Inhibitor and Chemotherapy in Advanced Non-Small Cell Lung Cancer（REACTIVE study）

Mar, 2021 - Dec, 2022

Kyoichi Kaira, Ou Yamaguchi
進行肺癌における免疫療法の効果を予測するためのPETと低酸素マーカーの可能性